COVID-19 大流行后，有报告称晚期头颈癌 (HNC) 的诊断延迟和患病率激增。我们对在我们中心接受筛查的患者中新诊断的 HNC 数量的影响进行了回顾性研究，以了解 COVID-19 对新诊断 HNC 数量的影响，以了解时间变化。我们调查了国际癌症控制联盟指南 - TNM 分类、是否存在主观症状根据 2019-2021 年期间到我们头颈外科就诊的首次 HNC 患者的医疗记录进行咨询时的初步治疗，并将其与大流行之前（2019 年）和大流行之后（2020-2021 年）进行比较.该研究总共纳入了1245名患者。 2019年、2020年和2021年患者人数分别为437人、417人和391人，表明疫情后呈下降趋势。当比较早期（0-II期）和晚期（III-IV期）HNC癌症的发病率时，早期癌症患者的比例有所下降。其中，T分类中观察到显着的原发肿瘤进展。初诊时无主观症状的患者数量明显减少。2020年和2021年大流行后，观察到早期癌症和原发肿瘤进展的HNC患者比例有所下降。早期恶性肿瘤的数量可能会减少。由于患者不愿意看医生，比例有所下降。© 2024 中华民国牙科科学协会。 Elsevier B.V. 的出版服务

Following the COVID-19 pandemic, there were reports of diagnostic delays and a surge in the prevalence of advanced head and neck cancer (HNC). We conducted a retrospective study on the impact of COVID-19 on the number of newly diagnosed HNC among patients who underwent screening at our center to understand the temporal changes.We investigated the Union for International Cancer Control guidelines-TNM classification, presence of subjective symptoms at the time of consultation, and initial treatment from the medical records of first-time patients with HNC who visited our head and neck surgery department during 2019-2021 and compared them with those before (2019) and after (2020-2021) the pandemic.A total of 1245 patients were included in the study. The number of patients were 437, 417, and 391 in 2019, 2020, and 2021, respectively, indicating a downward trend following the pandemic. When the incidence of early (stage 0-II) and advanced (stage III-IV) HNC cancers was compared, the proportion of patients with early-stage cancer declined. Among them, significant primary tumor progression was observed in T classification. The number of patients with no subjective symptoms at initial diagnosis was decreasing significantly.A decrease in the proportion of HNC patients with early-stage cancer and primary tumor progression was observed after the pandemic in 2020 and 2021. The number of early-stage malignancies may have dropped due to patients' unwillingness to visit a doctor.© 2024 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V.